Vitamin D, Cell Death Pathways, and Tuberculosis

Manik Retno Wahyunitisari1, Ni Made Mertaniasih1, Muhammad Amin2, Wayan T. Artama3, Eko B. Koendhori1

Departments of 1Medical Microbiology and 2Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, East Java, 3Department of Biochemistry, Faculty of Veterinary Medicine, Gadjah Mada University, Yogyakarta, Indonesia

Abstract

Background: Mycobacterium tuberculosis induces cellular necrosis that could promote spread of infection. The aim of this study is to analyze the effects of Vitamin D3 supplementation to improve the effectiveness of 2nd-line anti-tuberculosis (TB) drug therapy, especially in relation with cell death pathways. Methods: Mus musculus C3HeB/FeJ was randomly divided into four groups containing eight animals each. The 1st group (G1), consisting of mice that were intratracheally infected with multidrug-resistant strain of M. tuberculosis and sacrificed on 2-week postinfection to confirm successful infection. (G2) was a group of TB mice without therapy. Then, (G3) was a group of mice with the 2nd-line anti-TB therapy. The last group (G4) was a group of mice receiving not only the 2nd-line anti-TB therapy but also daily oral Vitamin D3 supplementation. Immunohistochemistry was used to measure expression of nuclear Vitamin D receptor, apoptosis marker cleaved caspase-3, cathelin-related antimicrobial peptide (CRAMP) and LC3B autophagy markers, necrosis marker RIPK3, and collagenase matrix metalloproteinase-1 (MMP1). The number of bacteria in the lung was calculated by colony forming units. The partial least square structural equation modeling with SmartPLS 3.2.6 software was used to analyze structural models among the variables. Results: Supplementation of Vitamin D3 on the 2nd-line anti-TB therapy increases Vitamin D3 receptor, CRAMP, LC3B, caspase-3 (P = 0.026, P = 0.000, P = 0.001), presses MMP1, and the number of bacteria (P = 0.010 and P = 0.000, respectively). The structural equation modeling analysis shows that increasing autophagy pathways reduces necrosis by lowering MMP1, whereas apoptosis reduces necrosis by decreasing the number of bacteria (each with indirect effects − 0.543 and − 0.544). Conclusion: A comprehensive analysis with the partial least square structural equation modeling shows decreasing necrosis requires increasing autophagy and apoptosis.

Keywords: Apoptosis, autophagy, matrix metalloproteinase-1, multidrug-resistant-tuberculosis, necrosis, Vitamin D3

Introduction

One of the challenges of tuberculosis (TB) eradication program is the increasing multidrug-resistant-TB, whereas the effectiveness of 2nd-line anti-TB is very low. There has been a lot of literature describing the role of Vitamin D in relation with the immunity of TB patients. An active form of Vitamin D binds to the Vitamin D3 receptor on the membrane and or cell nucleus to begin its activity. This study examines the role of Vitamin D3 supplementation in the TB cell death pathways and analyzes whether supplementation of Vitamin D can improve the effectiveness of 2nd-line anti-TB therapy as shown by decreasing matrix metalloproteinase-1 (MMP1) and the number of bacteria.

The viability of intracellular bacteria is influenced by cell death pathways. Apoptosis and autophagy are mycobactericidal, while necrosis precisely causes the bacteria to spread and infects the next cells. Mycobacterium tuberculosis induces apoptosis which involves caspase-3. Autophagy is preceded by the formation of autophagy membranes with microtubule-associated protein 1A/1B-light chain 3 (LC3) precursors, expressed more cathelicidin antimicrobial peptides which are referred as cathelin-related antimicrobial peptide (CRAMP) in mice. Cell necrosis occurs when cytosolic receptor interacting protein kinase 3 (RIPK3) undergoes translocation to mitochondria.

The partial least square structural equation modeling has enabled researchers to simultaneously estimate such complex interrelationships of several variables and build them into the model to improve the effectiveness of 2nd-line anti-tuberculosis (TB) drug therapy, especially in relation with cell death pathways.

Address for correspondence: Dr. Manik Retno Wahyunitisari, Department of Medical Microbiology, Faculty of Medicine, Airlangga University, Jalan Mayjen Moestopo 47, Surabaya 60131, East Java, Indonesia. E-mail: manik-r-w@fk.unair.ac.id

How to cite this article: Wahyunitisari MR, Mertaniasih NM, Amin M, Artama WT, Koendhori EB. Vitamin D, cell death pathways, and tuberculosis. Int J Mycobacteriol 2017;6:349-55.
developed theory-based models. The use of structural equation modeling in the analysis of intracellular signals is not new.[14-17]

**METHODS**

**Animals and experimental procedures**

Mus musculus C3HeB/FeJ (n = 8) aged 5–8 weeks were infected with 100 µl intratracheal (10⁶ CFU/ml) and divided randomly into four groups. The 1st group (G1) was the group to examine the success of intratracheal infection. The mice in group 1 were euthanized 2-week postinfection and observed whether they have pulmonary TB. (G2) was the group of TB mice without therapy. (G3) was the group of mice with the 2nd-line anti-TB therapy recommended by the Indonesian National Tuberculosis Control Program. (G4) was the group of mice which was not only treated with the 2nd-line anti-TB therapy but also received daily oral Vitamin D3 supplementation for 6 months.

Kanamycin (Sigma K1876) was injected im 150 mg/kg body weight once a day in 5 days/week. Pyrazinamide (Sigma P7136) 150 mg/kg body weight, levofloxacin (Sigma 28266) 200 mg/kg body weight, ethionamide (Sigma E6005-5G) 50 mg/kg body weight, cycloserine (Sigma 30020-1G) 300 mg/kg body weight, and Vitamin D3 (Dvion Drops, Merck) 1.25 IU/g body weight were given per intragastric tube once in 7 days/week. At the end of treatment, the mice were euthanized. The left lung tissue was processed for immunohistochemistry and the number of bacteria was obtained from the right lung tissue culture.

**Immunohistochemistry**

The used primary antibody included: anti-Vitamin D receptor antibody (ab3508, abcam), anti-cathelicidin antibody (ab64892 abcam), anti-LC3B antibody (ab63817, abcam), anti- MMP1 antibody (ab137332, abcam), anti-caspase3 (P17) (PA1961-1, BosterBio), and anti-RIPK3 (PA2242, BosterBio). The five different fields per section were analyzed by two independent investigators using the light microscope Olympus BX51 magnification 400x.

**Statistical analysis**

The statistical analysis was performed by using IBM SPSS 20.0 for Windows. The normality test was done using Shapiro–Wilk. The different test among different groups was analyzed using the one-way ANOVA test or the Kruskal–Wallis test, followed by a post hoc test either with the Tukey’s test or the Mann–Whitney test. The two-sided P < 0.05 were considered to indicate a statistically significant result.

Assessing the relationship among variables and predicting the theory-based structural model were done by applying the structural equation modeling test using the smartpls-3.2.6 GmbH.

**RESULTS**

**Supplementation of Vitamin D3 in the 2nd-line anti-tuberculosis increases the VDR expression**

Vitamin D is metabolized to 1,25-dihydroxyvitamin D. The hormonal form is the ligand for the Vitamin D receptor. Nuclear receptor-regulated transcription is cell specific. It is necessary to understand aspects of Vitamin D mechanisms of action to facilitate tissue-specific clinical application. Figure 1 visualizes Vitamin D3 receptor expression in lung tissue. Figure 2 shows supplementation of Vitamin D in the 2nd-line anti-TB which increases the Vitamin D3 receptor expression. M. tuberculosis can infect macrophages and alveolar epithelial type II pneumocytes.[18] Supplementation of Vitamin D3 promoted upregulation of Vitamin D-regulatory protein in infected cells.

**Cotreatment of Vitamin D3 and 2nd-line anti-tuberculosis drugs could enhance cathelin-related antimicrobial peptide and LC3B expression**

Vitamin D may reduce the risk of infection through multiple mechanisms. With a Vitamin D response element within its promoter sequence, CRAMP further is a target gene of Vitamin D. Figure 3 shows immunohistochemical analysis of CRAMP in lung tissue. Immunohistochemistry is a technique for investigating protein expression and localization within tissues. Supplementation of Vitamin D increases the antimicrobial protein cathelicidin which is accordance with previous research [Figure 4].[19-21]

LC3 is an autophagy membrane precursor which is expressed into three variants/posttranslational isoforms of LC3A, LC3B, and LC3C. With lipidation, the posttranslation of LC3B transforms into an 18 kDa LC3I cytosolic form and moves into a 16 kDa LC3II membrane form. Provision of Vitamin D3 increases the conversion of LC3B-I to LC3B-II.[22] Figure 5 shows LC3B expression in lung tissue during M. tuberculosis infection. Figure 6 shows changes in LC3B expression following D3 administration. The expression of LC3B is higher among Vitamin D3-supplemented group.

**Figure 1:** Immunohistochemistry of Vitamin D receptor in the lung. (a) Mice were treated with the only 2nd-line anti-tuberculosis drugs, immunoreactive VDR is noticed in macrophage (the star), activated lymphocyte (the red arrow) (b) mice were treated with the drugs in combination with the Vitamin D3. The number of Vitamin D receptor immunoreactive cells was increased by supplementation of Vitamin D (immunohistochemistry, ×1000)
Supplementation of Vitamin D3 in the 2nd-line anti-tuberculosis increases apoptosis

An apoptotic index is the number of positive caspase-3 cells in the cytosol per view field. Figure 7 shows that granulomas are dynamic lesions, both apoptosis and nonapoptosis macrophages are observed. Exogenous tumor necrosis factor (TNF) have been reported to elevate *M. tuberculosis*-mediated macrophage apoptosis. Figure 8 shows Vitamin D3 induces caspase-3.

This study demonstrates that exogenous Vitamin D upregulates caspase-mediated apoptosis. Apoptosis is a mechanism of infected cells to eliminate bacteria. It is the programmed cell death without causing an inflammatory reaction. Vitamin D has a beneficial role in the treatment of TB.

Figure 2: Supplementation of Vitamin D3 in the 2nd-line anti-tuberculosis increases the VDR expression.

Figure 3: Immunostaining for cathelin-related antimicrobial peptide in the lung section (a) mice were treated with the only 2nd-line anti-tuberculosis drugs and (b) mice were treated with the drugs in combination with the Vitamin D3. The number of cathelin-related antimicrobial peptide immunoreactive cells was increased by supplementation of Vitamin D (immunohistochemistry, ×1000).

Figure 4: Supplementation of Vitamin D in the 2nd-line anti-tuberculosis increases the cathelicidin antimicrobial protein.

Figure 5: Immunoreactivity of LC3B occurs in the lung. (a) Mice were treated with the only 2nd-line anti-tuberculosis drugs and (b) mice were treated with the drugs in combination with the Vitamin D3. The number of LC3B immunoreactive cells was increased by supplementation of Vitamin D (immunohistochemistry, ×1000).

Figure 6: Supplementation of Vitamin D in the 2nd-line anti-tuberculosis increases the LC3B expression.

Figure 7: (a) Caspase-3 expression in the lung tissue of mice treated with 2nd-line anti-tuberculosis drugs. The red arrow indicates an apoptotic macrophage and the star shows a nonapoptotic macrophage. (b) Mice were treated with the drugs in combination with the Vitamin D3. The number of Caspase-3 immunoreactive cells was increased by supplementation of Vitamin D (immunohistochemistry, ×1000).
Supplementation of Vitamin D3 enhances the effectiveness of 2nd-line anti-tuberculosis therapy by lowering the number of bacteria, expression of pulmonary collagenase enzyme matrix metalloproteinase-1, and cell necrosis

Figure 9 shows the mean bacterial count of the D3 supplemented group and the control group. Here, we show that Vitamin D3 have a positive impact on reducing bacterial load. The researcher noted that Vitamin D may help both innate and adaptive immunity.

Figure 10 shows immunohistochemical detection of MMP1 in lung tissue. The pulmonary tissue damage involves many factors. The study concludes that supplementation of Vitamin D decreases the expression of MMP1 [Figure 11], a collagenase enzyme that degrades types I, II, and III collagen. These data confirmed that Vitamin D regulate MMP1 expression in tissue where Vitamin D3 receptors are expressed.

The increased effectiveness of 2nd-line anti-TB was also measured by the decreasing the number of cell necrosis which causes bacteria to spread [Figure 12]. Necrosis is an inflammatory form of cell death. RIPK3 facilitates inflammation through damage-associated molecular patterns as well as nuclear factor-kappa B and result in the transcription of inflammatory cytokines. Figure 13 shows RIPK3 expression in response to D3 supplementation. Vitamin D as immunomodulator and anti-inflammatory agent mitigate cell stress. A comprehensive analysis with structural equation modeling concludes that supplementation of Vitamin D reduces cellular necrosis [Figures 14]. Autophagy reduce necrosis (RIPK3) by decreasing the pulmonary collagenase MMP1 with an indirect effect of −0.543. Autophagy has a protective effect on MMP-mediated cell injury.[24]

Apoptosis lowers RIPK3 by decreasing the number of bacteria with indirect effects of-0.544. Necrosis occurs when there is a high-intracellular bacillary load.[25] Apoptosis has control over the number of bacteria that is directly related to necrosis reduction.

DISCUSSION

There has been a lot of literature showing the association of TB with Vitamin D deficiency.[26-29] It is proposed that the lower level result from chronic infection. Calcitriol, which is also referred as the Vitamin D-active form, binds to the Vitamin D3 receptor in the transcription process. The vitamin D receptor is important for adequate immune function. Intervention using a daily and constant dosage of vitamin D3 for 6 months might be appropriate to improve the effectiveness of 2nd-line anti-TB drug therapy. Our study shows that Vitamin D supplementation upregulates VDR expression.

*M. tuberculosis* being trapped in immature phagosome. Vitamin D has mechanisms of controlling this evasion by inducing autophagy. The cathelicidin gene promoter region
Supplementation of Vitamin D3 enhances the effectiveness of 2nd-line anti-tuberculosis therapy by lowering the number of bacteria, expression of pulmonary collagenase enzyme matrix metalloproteinase-1, and cell necrosis

Supplementation of Vitamin D3 enhances the effectiveness of 2nd-line anti-TB therapy by lowering the number of bacteria. Since 1951, the antimycobacterial Vitamin D has been claimed to inhibit M. tuberculosis growth directly through upregulation of NO and NADPH oxidase, to induce maturation and activation of macrophages, to increase fusion of phagolysosomes and cathelicidin. Together with the Vitamin A, it reduces the transcription of tryptophan-aspartate-containing coat protein. The vitamin minimizes mycobacterium nutrition by inhibiting peroxisome proliferator-activated receptor γ which is responsible for differentiating macrophages into foam cells.

Oxidative stress and tuberculosis are closely related. Oxidative stress is also implicated in activation of MMP1. Vitamin D is a secosteroid, an immunosuppressive steroid, the anti-inflammatory effect arising from immune suppression. The protective effect was associated with the induction of endogenous antioxidant and decrease of lipid peroxidation. During treatment of pulmonary TB, we demonstrated that Vitamin D3 significantly inhibited MMP1 expression. Indeed, administration of Vitamin D also lowers MMP7, MMP9, increases TIMP, and lowers granzyme A which hydrolyzes type IV collagen.

Large level of reactive oxygen species and oxidative stress will induce cell death through necrotic pathway. The exacerbation of necrotic cell death and collagen destruction are a critical role causing caseous necrosis. Structural equation modeling is used to analyze the relationship between Vitamin D supplementation and necrotic cell death. There is an association between Vitamin D supplementation, autophagy, MMP1 expression, and necrotic cell death. Vitamin D-induced autophagy helps control massive tissue damage by pulmonary collagenase. Adjunctive Vitamin D therapeutic approaches aimed at decreasing necrosis and improving diseases outcomes.

The structural relationship between apoptosis and necrosis is also confirmed. Apoptosis lowers RIPK3 by decreasing the number of bacteria. Apoptosis itself is not intrinsically bactericidal but requires phagocytic uptake of the apoptotic body. Necrosis is not dependent on bacterial virulence. Necrosis was associated with the bacterial load. Necrosis occurs when there is a high-intracellular bacillary load.

Figure 12: Supplementation of Vitamin D3 in the 2nd-line anti-tuberculosis therapy decreases cell necrosis

Figure 13: RIPK3 expressions in the lung granuloma. (a) Mice were treated with the only 2nd-line anti-tuberculosis drugs and (b) mice were treated with the drugs in combination with the Vitamin D. The number of RIPK3 immunoreactive cells was reduced by supplementation of Vitamin D (immunohistochemistry, ×1000)
CONCLUSION

The cell death pathways are a fundamental process involved in the interaction between *M. tuberculosis* and infected cells. Decreasing necrosis requires increasing apoptosis and autophagy.

**Financial support and sponsorship**

This work was supported by The Ministry of Research, Technology, and Higher Education of the Republic of Indonesia: PBK 597/UN3.14/LT2017.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Miotto P, Cirillo DM, Migliori GB. Drug resistance in *Mycobacterium tuberculosis*: Molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. Chest 2015;147:1135-43.
2. Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis 2016;62:418-30.
3. Rook GA, Steele J, Fraher L, Barker S, Karmali R, O’Riordan J, et al. Vitamin D3, gamma interferon, and control of proliferation of *Mycobacterium tuberculosis* by human monocytes. Immunology 1986;57:159-63.
4. Eklund D, Persson HL, Larsson M, Welin A, Idh J, Paues J, et al. Vitamin D enhances IL-1β secretion and restricts growth of *Mycobacterium tuberculosis* in macrophages from TB patients. Int J Mycobacteriol 2013;2:18-25.
5. Harishankar M, Selvaraj P. Influence of Cdx2 and TaqI gene variants on Vitamin D3 modulated intracellular chemokine positive T-cell subsets in pulmonary tuberculosis. Clin Ther 2017;39:946-57.
6. Norval M, Coussens AK, Wilkinson RJ, Bornman L, Lucas RM, Wright CY, et al. Vitamin D status and its consequences for health in south africa. Int J Environ Res Public Health 2016;13. pii:E1019.
7. Juric Smith KL, Lee S. Inhibition of apoptosis by Rv2456c trough nuclear factor-κB extends the survival of *Mycobacterium tuberculosis*. Int J Mycobacteriol 2016;5:426-36.
8. Dubey RK. Assuming the role of mitochondria in mycobacterial infection. Int J Mycobacteriol 2016;5:379-83.
9. Lam A, Prabhu R, Gross CM, Riesenburg LA, Singh V, Aggarwal S, et al. Role of apoptosis and autophagy in tuberculosis. Am J Physiol Lung Cell Mol Physiol 2017;313:L218-29.
10. Aguilo N, Uranga S, Marinova D, Martin C, Pardo J. Bim is a crucial regulator of apoptosis induced by *Mycobacterium tuberculosis*. Cell Death Dis 2014;5:e1343.
11. Kimura T, Jia J, Kumar S, Choi SW, Gu Y, Mudd M, et al. Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy. EMBO J 2017;36:42-60.
12. Selvaraj P, Harishankar M, Afsal K. Vitamin D: Immuno-modulation and tuberculosis treatment. Can J Physiol Pharmacol 2015;93:377-84.
13. Zhao X, Khan N, Gan H, Tzelepis F, Nishimura T, Park SY, et al. Bel XL mediates RIPK3 dependent necrosis in *M. tuberculosis* infected macrophages. Mucosal Immunol 2017. doi: 10.1038/mi.2017.12. [Epub ahead of print].
14. Xie J, Bentler PM. Covariance structure models for gene expression microarray data. Struct Equ Modeling 2003;10:566-82.
15. Xiong M, Li J, Fang X. Identification of genetic networks. Genetics 2004;166:1037-52.
16. Wu X, Sharpe K, Zhang T, Chen H, Zhu W, Li E, et al. Comparative Genetic Pathway Analysis Using Structural Equation Modeling. Proceeding of IEEE First International Conference on Computational Advances in Bio and Medical Sciences (ICCABS 2011): 3-5 February 2011; Orlando. 2011, Washington, DC, USA: IEEE Computer Society; 2011. p. 190-5.
17. Chan NC, Lau KM, Cheng KC, Chan NP, Ng MH. A multi-locus approach to characterization of major quantitative trait loci influencing Hb F regulation in Chinese β-thalassemia carriers. Hemoglobin 2016;40:400-4.
18. Smith I. *Mycobacterium tuberculosis* pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003;16:463-96.
Wahyunitisari, et al.: Vitamin D and cell death pathways

19. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. IHN-gamma- and TNF-independent Vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin. J Immunol 2007;178:7190-8.

20. Afshari S, Selvaraj P. Effect of 1,25-dihydroxyvitamin D3 on the expression of mannose receptor, DC-SIGN and autophagy genes in pulmonary tuberculosis. Tuberculosis (Edinb) 2016;99:1-10.

21. Chedchadai S, Zughair SM, Hào L, Kempker RR, Blumberg HM, Ziegler TR, et al. The effects of first-line anti-tuberculosis drugs on the actions of Vitamin D in human macrophages. J Clin Transl Endocrinol 2016;6:23-9.

22. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 2012;8:e1002689.

23. Anandaiah A, Sinha S, Bole M, Sharma SK, Kumar N, Luthra K, et al. Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced toll-like receptor signaling pathway in vitro. Infect Immun 2013;81:2-10.

24. Chao CL, Chuang CP, Cheng YF, Lee KR, Chang Y, Cheng SP, et al. The protective role of autophagy in matrix metalloproteinase-mediated cell transmigration and cell death in high-glucose-treated endothelial cells. Inflammation 2016;39:830-8.

25. Rodrigues MF, Barsante MM, Alves CC, Souza MA, Ferreira AP, Amarante-Mendes GP, et al. Apoptosis of macrophages during Mycobacterium bovis infection: Correlation with intracellular bacillary load and cytokine levels. Immunology 2009;128:e691-9.

26. Brodie MJ, Boobis AR, Dollery CT, Hillyard CJ, Brown DJ, Macintyre I, et al. Rifampicin and Vitamin D metabolism in man [proceedings]. Br J Clin Pharmacol 1980;9:286P-7P.

27. Brodie MJ, Boobis AR, Hillyard CJ, Ayebasekere G, Macintyre I, Park BK, et al. Effect of isoniazid on Vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther 1981;30:363-7.

28. Azam F, Shaheen A, Arshad R. Frequency of hypovitaminosis D and its associated risk factors in newly diagnosed pulmonary tuberculosis patients. Pak J Med Sci 2016;32:480-4.

29. Huang SJ, Wang YH, Liu ZD, Cao WL, Han Y, Ma AG, et al. Vitamin D deficiency and the risk of tuberculosis: A meta-analysis. Drug Des Devel Ther 2017;11:91-102.

30. Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, Wheelwright M, et al. Convergence of IL-1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. PLoS One 2009;4:e5810.

31. Gombart AF, Saito T, Koefler HP. Exaption of an ancient alu short interspersed element provides a highly conserved Vitamin D-mediated innate immune response in humans and primates. BMC Genomics 2009;10:321.

32. Dhwany P, Wei R, Sun C, Gombart AF, Koefler HP, Diamond G, et al. C/EBPα and the Vitamin D receptor cooperate in the regulation of cathelicidin in lung epithelial cells. J Cell Physiol 2015;230:464-72.

33. Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, et al. C/EBPalpha and the Vitamin D receptor cooperate in the regulation of cathelicidin. Mol Pathol 2007;69:216-22.

34. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009;6:231-43.

35. Jo EK. Innate immunity to mycobacteria: Vitamin D and autophagy. Cell Microbiol 2010;12:1026-35.

36. Colecchia D, Strambi A, Sanzone S, Lavaroni C, Rossi M, Dall’Armi C, et al. MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP proteins. Autophagy 2012;8:1724-40.

37. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3:542-5.

38. Zhao X, Bausano B, Pike BR, Newcomb-Fernandez JK, Wang KK, Shohami E, et al. TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary sepho-hepacommal cultures. J Neurosci Res 2001;64:121-31.

39. Rockett KA, Brookes R, Udalova I, Vidal V, Hill AV, Kwiatkowski D, et al. 1,25-dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line. Infect Immun 1998;66:3514-21.

40. Brüne B. Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 2003;10:864-9.

41. Dieryck J. Influence of Vitamin D2 on the growth of the tubercle bacillus. Acta Clin Belg 1951;6:79-80.

42. Greenstein RJ, Su L, Brown ST. Vitamin A & D inhibit growth of mycobacteria in radiometric culture. PLoS One 2012;7:e29631.

43. Crowle AJ, Ross EJ, May MH. Inhibition by 1.25(OH)2-Vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun 1987;55:2945-50.

44. Hmama Z, Sendide K, Talal A, Garcia R, Dobos K, Reiner NE, et al. Quantitative analysis of phagolysosome fusion in intact cells: Inhibition by mycobacterial lipoarabinomannan and rescue by an 1α,25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway. J Cell Sci 2004;117:2131-40.

45. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007;179:2060-3.

46. Anand PK, Kaul D. Vitamin D3-dependent pathway regulates TACO gene transcription. Biochem Biophys Res Comm 2003;310:876-7.

47. Salamon H, Bruiners N, lakehal K, Shi L, Ravi J, Yamaguchi KD, et al. Cutting edge: Vitamin D regulates lipid metabolism in Mycobacterium tuberculosis infection. J Immunol 2014;193:30-40.

48. Shab-Bidar S, Neyestani TR, Djazaery A. The interactive effect of 1, 25-dihydroxyvitamin D3 and Vitamin D receptor gene variants on pulmonary tuberculosis. Clin Immunol 2009;133:126-31.

49. Jo EK. Innate immunity to mycobacteria: Vitamin D and autophagy. Cell Microbiol 2010;12:1026-35.

50. Vidyarani M, Selvaraj P, Raghavan S, Narayanan PR. Regulatory role of 1,25 dihydroxyvitamin D3 and Vitamin D receptor gene variants on intracellular granulocyte A expression in pulmonary tuberculosis. Exp Mol Pathol 2009;86:69-73.

51. Shohami E, Tezera L, Bielecka MK, Workman V, et al. Mycobacterial suppression of mycobacteria in radiometric culture. PLoS One 2012;7:e29631.

52. Butler RE, Brodin P, Jang J, Jang MS, Robertson BD, Gicquel B, et al. The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. PLoS One 2012;7:e47573.